Cyclophilin A (CyPA) is an abundantly expressed intracellular protein. It exerts a variety of functions due to its peptidyl -prolyl cis -trans isomerase (PPIase) activity. When released into the extracellular space, CyPA binds to its extracellular receptor CD147 (EMMPRIN) and thereby initiates a cascade of inflammatory processes. Recent data indicate that both extra-and intracellular CyPA significantly contribute to cardiovascular inflammation, myocardial ischaemia and reperfusion injury, and myocardial remodelling processes. Thus, CyPA appears to represent a novel target to treat vascular and myocardial inflammation.
Introduction
In 1984, cyclophilin A (CyPA) was characterized as a specific intracellular binding protein for cyclosporin A (CsA). 1 The immunosuppressive activity of CsA is mediated by an intracellular CsA -CyPA complex, which blocks calcineurin-dependent activation of nuclear factor activating T-cell (NFAT). 2 -4 Notably, this immunosuppressive effect strictly depends on the binding of the CsA -CyPA complex to calcineurin. The physiological functions of CyPA (in the absence of CsA) are completely different ( Figure 1A ). CyPA has an enzymatic activity as a peptidyl -prolyl cis -trans isomerase (PPIase) catalysing cis -trans isomerization of peptidyl -prolyl bonds at proline residues ( Figure 1B ).
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Expression and release of CyPA
CyPA is a primarily intracellular protein, which is expressed abundantly in all mammalian cell types. As a housekeeping protein, it accounts for 0.4% of the complete intracellular proteome. 7, 8 Interestingly, various cell types have been described to secrete CyPA into the extracellular space. For example, CyPA is released by macrophages upon stimulation with LPS or high levels of glucose 9, 10 or during foam cell formation in vitro. 11 Moreover, the release of CyPA by vascular smooth muscle cells appears to highly promote the pathophysiology of vascular inflammation in abdominal aortic aneurysms, vascular restenosis, and atherosclerosis. 12 -14 In addition, both activated platelets and hypoxic cardiomyoctes have been shown to secrete CyPA into the extracellular space. 15, 16 The exact mechanism of the CyPA release in these cells has not been described. However, a recent report describes that the acetylation of CyPA is required for its secretion into the extracellular space in vascular smooth muscle cells. Moreover, acetylated CyPA seems to exert a more pronounced inflammatory activity than unmodified CyPA. 17 In patients, enhanced levels of soluble extracellular CyPA can be detected under classical inflammatory conditions, e.g. in synovial fluids of patients with rheumathoid arthritis, 18 in serum of patients with sepsis, 19 in nasal fluids of patients with asthma, 20 and in plasma of patients with Type 2 diabetes. 9 Recently, enhanced serum CyPA has been characterized as a biomarker of coronary artery disease as well. 21 In addition to CyPA, cyclophilin B (CyPB) is released from a variety of cells and exerts proinflammatory activities as well. 22 In contrast to CyPA, CyPB is constitutively secreted by tissue resident cells (e.g. fibroblasts and chondrocytes). Notably, CyPB seems to be a component of the extracellular matrix and can be released by matrix metalloproteinases (MMPs). 23, 24 CyPD is an isoform localized in the mitochondria and facilitates the formation of the permeability transition pore, and thus crucially involved in ischaemia and reperfusion injury.
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Extracellular CyPA and its receptor EMMPRIN (CD147)
CyPA is secreted by various cell types upon stimulation, e.g. LPS-activated macrophages and -stimulated smooth muscle cells, 10, 27 or released upon cell death. Extracellularly, CyPA represents a potent chemotactic factor for leucocytes (T-cells, monocytes, and neutrophilic and eosinophilic granulocytes 
Extracellular CyPA and EMMPRIN as mediators of inflammation in non-cardiovascular mouse models
The pathophysiological relevance of CyPA/EMMPRIN interaction for inflammatory processes has been studied in various non-cardiovascular animal models: in a mouse model of allergic lung inflammation, CyPA levels were found enhanced in bronchoalveolar lavages compared with control animals and CyPA was identified as an important driver of T-cell recruitment. 30, 44 Systemic treatment with an EMMPRINblocking antibody dramatically reduced lung inflammation, which supports the role of EMMPRIN as the corresponding receptor for CyPA in this model. 44 In addition, in a mouse model of rheumatoid arthritis, antibody treatment directed against the EMMPRIN-CyPA interaction (clone RL 73.2) resulted in severly reduced TNF-a and myeloperoxidase levels in joints and reduced disease severity score as well. 45 Based on these and other studies, the interaction of extracellular CyPA with EMMPRIN represents an established pair of inflammatory factors in autoimmune diseases. 46, 47 In addition, EMMPRIN is recognized as an essential mediator of neuroinflammation regulating leucocyte transmigration and MMP release into the CNS. 51 
Vascular remodelling
Inflammation plays a critical role in the pathogenesis of cardiovascular diseases. 52 13 In this model, the main mechanism was attributed to inflammatory activities of vascular smooth muscle cellderived extracellular CyPA, which was required for ROS generation and MMP-2 activity. 13 Both are key players for aneurysm formation. Additionally, expression of inflammatory cytokines such as interleukin-6 and recruitment of inflammatory cells into the vascular walls were dramatically reduced in the absence of CyPA. 12 Nevertheless, EMMPRIN is expressed in human samples of aortic aneurysms and remains to be investigated. 54 
Atherosclerosis
Atherosclerosis is an inflammatory disease. 55 MMP activity is thought to promote both atheroprogression and plaque rupture. the role of EMMPRIN for T-cell-regulated inflammatory processes in atherosclerosis awaits future investigation. However, both extra-and intracellular CyPA seem to play a role in atherosclerosis: in CyPA-deficient mice, a decreased low-density lipoprotein uptake into the vascular wall could be detected. This could be ascribed to a reduced expression of scavenger receptors in the vascular wall such as CD36 and SR-A. The exact mechanism how intracellular CyPA regulates the expression of scavenger receptors is unclear. 14 In addition, in vivo endothelial cells lacking CyPA revealed a reduced expression of vascular cell adhesion molecule-1. Further experiments with human umbilical vein endothelial cells revealed that the endothelial nitric oxide (NO) synthase (eNOS) production was affected by intracellular CyPA via reduction of Kruppel-like factor 2 expression and repression of eNOS transcription.
14 Finally, endothelial cells lacking CyPA were more resistant to TNF-induced apoptosis ( Figure 2 ). In addition, it has been reported that intracellular CyPA can interact with apoptosis-inducing factor upon cerebral hypoxia ischaemia to form a proapoptotic DNA degradation complex leading to neuronal cell death in vitro and in vivo. However, the authors did not differentiate between intra-and extracellular CyPA in their in vivo model by using CyPA-deficient mice. 67 Extracellular CyPA promotes endothelial cell apoptosis in association with increased c-Jun N-terminal kinase and p38 activities. 68 Notably, in neurological disorders like Alzheimer's disease, extracellular CyPA reveals neuroprotective effects. 69 Consistent with the above-discussed animal data, CyPA is enhanced in patients with Type 2 diabetes as well as in the plasma of patients with symptomatic coronary artery disease and correlates well with the severity of coronary artery disease as well as with the amount of classical cardiovascular risk factors (Figure 3) .
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4. Platelet function and (athero)thrombosis EMMPRIN has recently been identified an characterized on platelets. 41 EMMPRIN is located in the alpha granules in the open canalicular system (according to electron microscopy and sucrose gradient ultracentrifugation). Binding of recombinant soluble EMMPRIN induces platelet degranulation with enhanced surface expression of CD40L and P-selectin, suggesting that EMMPRIN-EMMPRIN interaction activates platelets. Incubation of platelets with monocytes leads to an NF-k-B-dependent induction of inflammatory cytokines (e.g. IL-6 and TNF-a) and MMP-9 in monocytes via EMMPRIN. 36 In patients, the expression of EMMPRIN on platelets appears to correlate with the extent of coronary artery disease. 70 Moreover, we could provide evidence that EMMPRIN can not only work as a signalling receptor, but also as an adhesion receptor through its homotypic interaction with EMMPRIN and the platelet collagen receptor glycoprotein VI (GPVI). 36 This concept was further supported by the observation that EMMPRIN-GPVI binding is involved in platelet-monocyte interactions in vivo augmenting monocyte recruitment to the vascular wall. 43 Whereas the influence of extracellular CyPA on platelets has not been investigated yet, recently it has been reported that intracellular CyPA in platelets is crucially involved in platelet function. 71, 72 CyPA-deficient mice are protected from arterial thrombus formation upon vascular injury. This effect could be ascribed to the CyPAdependent phosphorylation of the Ca 2+ sensor tromal interaction molecule 1. Thus, CyPA-deficient platelets revealed a dramatically reduced activation-induced Ca(2+) mobilization from intracellular stores as well as extracellular Ca 2+ influx. 72 
Myocardial infarction
Monocytes in patients with acute myocardial infarction reveal an enhanced EMMPRIN surface expression, suggesting a role of EMMPRIN in plaque instability via the above-described mechanisms. 42 In a mouse model of myocardial ischaemia and reperfusion, Ppia 2/2 mice showed reduced infarct size which was accompanied by a preserved left ventricular ejection fraction. 73 In addition, neutrophil and monocyte recruitment was dramatically reduced. Comparable effects were noted in Ppia
mice treated with mAb anti-CD147. In vitro data revealed the involvement of EMMPRIN as a main chemotactic receptor. The role of EMMPRIN was further supported by the fact that the combination of Ppia 2/2 mice with anti-CD147 treatment did not yield further protection after ischaemia and reperfusion. 73 In this study, the inhibition of EMMPRIN via an antibody applied immediately before the reopening of the infarct-related artery (left anterior descending) still leads to myocardial protection upon ischaemia and reperfusion. 73 Thus, it is tempting to speculate that CyPA and EMMPRIN are potential targets in preventing ischaemia and reperfusion injury. Indeed, it has been reported that treatment with CsA, an inhibitor of CyPA, reduces infarct size in patients with acute myocardial infarction. 74 However, cyclosporine A is a potent inhibitor of cyclophilin D as well, which is a powerful mediator of ischaemia and reperfusion injury. 75 In a mouse model of coxsackie virus B3-induced myocarditis, CyPA and EMMPRIN were found up-regulated and CyPA was found to be required for an effective recruitment of macrophages and T-cells to the infected myocardium. The deficiency of CyPA or the pharmacological inhibition of CyPA in wild-type mice reduced myocardial infiltration with inflammatory cells and reduced the remodelling process leading to fibrosis. 77 Consistent with these animal data, an up-regulation of myocardial EMMPRIN and CyPA expression was noted in patients with inflammatory cardiomyopathies, suggesting these two proteins as novel biomarkers for inflammatory cardiomyopathy. 78 Finally, recent data suggest that the enhanced presence of CyPA in endomyocardial biopsies predicts a poor prognosis in patients with non-ischaemic cardiomyopathies. 79 
Inflammatory and non-inflammatory cardiomyopathies

Conclusion and future directions
In conclusion, CyPA is an important mediator of cardiovascular inflammation and seems to be a suitable target for prohibiting or treating inflammatory cardiovascular processes. Despite many in vitro studies using CsA as a blocking agent against CyPA, CsA is not an ideal candidate to block CyPA-mediated effects in vivo because of the immunosuppressive properties of the CyPA -CsA complex. CsA has been successfully applied in patients with acute myocardial infarction: 74 58 patients were treated either with saline or with CsA (2.5 mg per kg) on top of the current guideline-conform treatment. Serum parameters for infarct size such as troponin or creatine kinase showed a significant reduction in the CsA-treated group. Notably, no adverse side effects were observed. Moreover, in patients with systemic lupus erythematosus, patients treated with CsA revealed an reduced carotid intima-media thickness compared with risk-adjusted healthy controls, which may support the concept that blocking cyclophilins can attenuate human atherosclerosis. 80 However, there are discrepant findings about CsAmediated effects on atherosclerosis. 81 The complex effect of CsA on cardiovascular cells including lipoprotein metabolism and the inhibition of other cyclophilins apart from CyPA may account for this discrepancy. 81 Thus, modified CsA derivates are needed to achieve a more compartment-specific inhibition of cyclophilins. The non-immunosuppressive cyclopsorin A analogue NIM811 is such a compound blocking intra-and extracellular cyclophilins without affecting calcineurin activity. 77, 82 It has been used in several in vivo studies. 47 However, it can pass the cell membrane and block intracellular cyclophilins such as cyclophilin D. 75 Thus, NIM811 may cause side effects by affecting intracellular cyclophilins. Based on these considerations, a modified CsA analogue has been designed, which cannot pass the cell membrane and, therefore, specifically blocks extracellular cyclophilins. 47, 83 This compound has been successfully applied in a mouse model of allergic lung inflammation. 47 Taken together, future studies have to further evaluate the clinical impact of pharmacological strategies specifically directed against extracellular CyPA or its receptor EMMPRIN in cardiovascular pathologies associated with myocardial inflammation, ischaemia, and/or remodelling. 84 Conflict of interest: none declared. Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases
